Targeting JNK for therapeutic benefit: From junk to gold?

Nature Reviews Drug Discovery

Volumn 2, Issue 7, 2003, Pages 554-565

  Manning, Anthony M ^a   Davis, Roger J ^b  

^a ROCHE BIOSCIENCE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE DERIVATIVE; AMINO ACID DERIVATIVE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTHRACENE DERIVATIVE; CYTOKINE; ENZYME INHIBITOR; GROWTH FACTOR; HYDRAZIDE DERIVATIVE; INDOLE DERIVATIVE; INDOLIZINE DERIVATIVE; OXINDOLE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SULFONAMIDE; SULFONE DERIVATIVE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE;

CANCER; CELL PROLIFERATION; CELL SURVIVAL; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; MALIGNANT TRANSFORMATION; METABOLIC DISORDER; NOCICEPTIVE STIMULATION; NONHUMAN; PATHOGENESIS; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; ANIMAL; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INFLAMMATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; NEURODEGENERATIVE DISEASES; OBESITY; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0038004740     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1132     Document Type: Review

References (103)

1. Kyriakis, J. M. & Avruch, J. pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. J. Biol. Chem. 265, 17355-17363 (1990).
2. Hibi, M., Lin, A., Smeal, T., Minden, A. & Karin, M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7, 2135-2148 (1993).
3. Adler, V., Polotskaya, A., Wagner, F. & Kraft, A. S. Affinity-purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. J. Biol. Chem. 267, 17001-17005 (1992).
4. Derijard, B. et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76, 1025-1037 (1994).
5. Kyriakis, J. M. et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369, 156-160 (1994).
6. Davis, R. J. Signal transduction by the JNK group of MAP kinases, Cell 103, 239-252 (2000).
7. Gupta, S. et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15, 2760-2770 (1996).
8. 2-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol. Cell Biol. 23, 2871-2882 (2003).
9. Tournier, C. et al. Requirement of JNK for stress-induced activation of the cytochrome o-mediated death pathway. Science 288, 870-874 (2000).
10. Lawler, S., Fleming, Y, Goedert, M. & Cohen, P. Synergistic activation of SAPK1/JNK1 by two MAP kinase kinases in vitro. Curr. Biol. 8, 1387-1390 (1998).
11. Tournier, C. et al. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev. 15, 1419-1426 (2001).
12. Enslen, H. & Davis, R. J. Regulation of MAP kinases by docking domains. Biol. Cell 93, 5-14 (2001).
13. Morrison, D. & Davis, R. J. MAP kinase scaffold proteins in mammals. Annu. Rev. Dev. Cell Biol. (in the press).
14. Harper, S. J. & LoGrasso, P. Inhibitors of the JNK signaling pathway. Drugs of the Future 26, 957-973 (2001).
15. Maroney, A. C. et al. CEP-1347 (KT7515), a synthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. 276, 25302-25308 (2001).
16. Manning, A. M. & Mercurio, F. Transcription inhibitors in inflammation. Exp. Opin. Invest. Drugs 6, 555-567 (1997).
17. Swantek, J. L., Cobb, M. H. & Geppert, T. D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor-α (TNF-α) translation: glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. Mol. Cell. Biol. 17, 6274-6282 (1997).
18. Ishizuka, T. et al. Mast cell tumor necrosis factor α production is regulated by MEK kinases. Proc. Natl Acad. Sci. USA 94, 6358-6363 (1997).
19. Gum, R., Wang, H., Lengyel, E., Juarez, J. & Boyd, D. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene 14, 1481-1493 (1997).
20. Han, Z. et al. Jun-N-terminal kinase in rheumatoid arthritis. J. Pharm. Exp. Therap. 291, 124-130 (1999).
21. Han, Z. et al. c-Jun N-terminal kinase is required for metalloproteinase (MMP) expression in synoviocytes and regulates bone destruction in adjuvant arthritis. J. Clin. Invest. 108, 73-81 (2001).
22. Clancy, R. et al. Activation of stress-activated protein kinase in osteoarthritis cartilage: evidence for nitric oxide dependence. Osteoarthritis Cartilage 9, 294-299 (2002).
23. Bennett, B. L. et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl Acad. Sci. USA 98, 13681-13686 (2001).
24. Han, Z., Chang, L., Yamanishi, Y., Karin, M. & Firestein, G. S. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum. 46, 818-823 (2002).
25. Eynott, P. R., Adcock, I. M. & Chung, P. The effects of selective c-Jun N-terminal kinase inhibition in a sensitized Brown Norway rat model of allergic asthma. Am. J. Respir. Crit. Care Med. 49, S102 (2001).
26. Sabapathy, K. et al. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr. Biol. 9, 116-125 (1999).
27. + thymocytes. J. Exp. Med. 188, 1817-1830 (1998).
28. Dong, C. et al. JNK is required for effector T-cell function but not for T-cell activation. Nature 405, 91-94 (2000).
29. Dong, C. et al. Defective T cell differentiation in the absence of Jnk1. Science 282, 2092-2095 (1998).
30. + T cells to Th1 cells requires MAP kinase JNK2. Immunity 9, 575-585 (1998).
31. + T cell-mediated antiviral immunity. J. Exp. Med. 195, 801-810 (2002).
32. + T call activation. J. Exp. Med. 195, 811-823 (2002).
33. Su, B. et al. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77, 727-736 (1994).
34. + T cells. Science 271, 1272-1276 (1996).
35. Rincon, M., Flavell, R. A. & Davis, R. J. Signal transduction by MAP kinases in T lymphocytes. Oncogene 20, 2490-2497 (2001)
36. Kuan, C. Y. et al. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22, 667-676 (1999).
37. Yang, D. D. et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389, 865-870 (1997).
38. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J. & Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331 (1995).
39. Le-Niculescu, H. et al. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell Biol. 19, 751-763 (1999).
40. Bruckner, S. R. et al. JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons. J. Neurochem. 78, 298-303 (2001).
41. Scheuner, D. et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864-870 (1996).
42. Morishima, Y. et al. β-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21, 7551-7560 (2001).
43. Zhu, X. et al. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease J. Neurochem. 76, 435-441 (2001).
44. Pei, J-J. et al. Localization of active forms of c-Jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J. Alzheimer's Dis. 3, 41-48 (2001).
45. Reynolds, C. H., Utton, M. A., Gibb, G. M., Yates, A. & Anderton, B. H. Stress-activated protein kinase/c-Jun N-terminal kinase phosphorylates Tau protein. J. Neurochem. 68, 1736-1744 (1997).
46. Shoji, M. et al. JNK activation is associated with intracellular β-amyloid accumulation. Mol. Brain Res. 85, 221-233 (2001).
47. Reynolds, C. H., Betts, J. C., Blackstock, W. P., Nebreda, A. P. & Anderton, B. H. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and p38, and glycogen synthase kinase-3β. J. Neurochem. 74, 1587-1595 (2001).
48. Anglade, P. et al Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12, 25-31 (1997).
49. Xia, X. G. et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 10433-10438 (2001).
50. Mattson, M. P. Apoptosis in neurodegenerative disorders. Nature Rev. Mol. Cell Biol. 1, 120-129 (2000).
51. Herdegen, T. et al. Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. J. Neurosci. 18, 5124-5135 (1998).
52. Must, A. et al. The disease burden associated with overweight and obesity. JAMA 282, 1523-1529 (1999).
53. Facchini, F. S., Hua, N. W., Reaven, G. M. & Stoohs, R. A. Hyperinsulinemia: the missing link among oxidative stress and age-related diseases? Free Rad. Biol. Med. 29, 1302-1306 (2000).
54. Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389, 610-614 (1997).
55. Withers, D. J. & White, M. F. Insulin action and type 2 diabetes: lessons from knockout mice. Curr. Opin. Endocrinol. Diab. 6, 141-145 (1999).
56. Withers, D. J. et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-904 (1998).
57. Lee, Y. H., Giraud, J., Davis, R. J. & White, M. F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 278, 2896-2902 (2003).
58. Standaert, M. L. et al. Effects of knockout of the protein kinase C β gene on glucose transport and glucose homeostasis. Endocrinology 140, 4470-4477 (1999).
59. Hirosumi, J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333-337 (2002).
60. Adjei, A. A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl Cancer Inst. 93, 1062-1074 (2001).
61. Smeal, T, Binetruy, B., Mercola, D. A., Birrer, M. & Karin, M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354, 494-496 (1991).
62. Schutte, J., Minna, J. D. & Birrer, M. J. Deregulated expression of human c-Jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc. Natl Acad. Sci. USA 86, 2257-2261 (1989).
63. Johnson, R., Spiegelman, B., Hanahan, D. & Wisdom, R. Cellular transformation and malignancy induced by ras require c-Jun. Mol. Cell Biol. 16, 4504-4511 (1996).
64. Eferl, R. et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112, 181-192 (2003).
65. Schreiber, M. et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 13, 607-619 (1999).
66. Ip, Y. T. & Davis, R. J. Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development. Curr. Opin. Cell Biol. 10, 205-219 (1998).
67. Potapova, O. et al. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272, 14041-14044 (1997).
68. Potapova, O. et al. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J. Biol. Chem. 275, 24767-24775 (2000).
69. Behrens, A., Jochum, W., Sibilia, M. & Wagner, E. F. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 9, 2657-2663 (2000).
70. Kennedy, N.J. et al. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev. 17, 629-637 (2003).
71. 2-terminal kinase. Mol. Cell Biol. 22, 4929-4942 (2002).
72. 2-terminal kinase 3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors. J. Hum. Genet. 46, 182-187 (2001).
73. Nishina, H. et al. Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nature 385, 350-353 (1997).
74. Tournier, C. et al. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev. 15, 1419-1426 (2001).
75. Teng, D. H. et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 57, 4177-4182 (1997).
76. Kim, H. L. et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 61, 2833-2837 (2001).
77. Yoshida, B. A. et al. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 59, 5483-5487 (1999).
78. Yamada, S. D. et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 62, 6717-6723 (2002).
79. 2-terminal kinase in transformed B lymphoblasts. Nature Genet. 32, 201-205 (2002).
80. Dumas, J. Protein kinase inhibitors: emerging pharmacophores 1997-2000. Exp. Opin. Ther. Patents 11, 405-429 (2001).
81. Gray, N. S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998).
82. Zhang, F., Strand, A., Robbins, D., Cobb, M. H. & Goldsmith, E. J. Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution. Nature 367, 704-711 (1994).
83. Wilson, K. P. et al. Crystal structure of p38 mitogen-activated protein kinase. J. Biol. Chem. 271, 27696-27700 (1996).
84. Xie, X. et al. Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. Structure 6, 983-991 (1998).
85. Bennett, B. L. et al. WO 0112609 (2001).
86. Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204 (2003).
87. Kois, A. et al. WO 200246170 (2002).
88. Press release, dated 10/21/2002; see http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=celg&script= 410&layout=9&item_id=346725.
89. Halazy, S., Church, D., Camps, M. & Gotteland, J. P. WO 0147920 (2001).
90. Arkinstall, S. et al. WO 0123379 (2001).
91. Arkinstall, S. et al. WO 0123378 (2001).
92. Arkinstall, S. et al. WO 0123382 (2001).
93. Salituro, F. G. et al. WO 0064872 (2000).
94. Green, J. et al. WO 0112621 (2001).
95. Ohkawa, S., Naruo, K., Miwatashi, S., Kimura, H. & Kawamoto, T. WO 2002062792 (2002).
96. Corbett, W. L. & Luk, K.-C. & Mahaney, P. E. WO 0035909 (2000).
97. Luk, K.-C., Mahaney P. E. & Mischke, S. G. WO 0035906 (2000).
98. Luk, K.-C. & Michoud, C. WO 0035921 (2000).
99. Radcliffe, A. J. et al. WO 2003024967 (2003).
100. Oinuma, H., Ohi, N., Sato, N. & Seshimo, H. WO 2002083648 (2002).
101. Graczyk, P. et al. WO 2002081475 (2002).
102. Lograsso, P et al. WO 200191749 (2001).
103. Weston, C. R. & Davis, R. J. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12, 14-21 (2002).